SomnoMed Limited
SOMNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $111 | $92 | $84 | $73 |
| % Growth | 21.6% | 9.6% | 15.2% | – |
| Cost of Goods Sold | $45 | $37 | $38 | $33 |
| Gross Profit | $67 | $55 | $46 | $39 |
| % Margin | 59.9% | 60.2% | 54.7% | 53.9% |
| R&D Expenses | $2 | $1 | $1 | $1 |
| G&A Expenses | $20 | $18 | $14 | $14 |
| SG&A Expenses | $61 | $44 | $39 | $34 |
| Sales & Mktg Exp. | $23 | $26 | $24 | $20 |
| Other Operating Expenses | $0 | $18 | $10 | $9 |
| Operating Expenses | $63 | $63 | $50 | $43 |
| Operating Income | $4 | -$8 | -$4 | -$4 |
| % Margin | 3.2% | -9.1% | -4.9% | -5.7% |
| Other Income/Exp. Net | -$4 | -$3 | -$3 | $1 |
| Pre-Tax Income | -$1 | -$11 | -$7 | -$3 |
| Tax Expense | $3 | $1 | $1 | $1 |
| Net Income | -$3 | -$12 | -$8 | -$4 |
| % Margin | -3.1% | -13.4% | -9.6% | -6.1% |
| EPS | -0.016 | -0.1 | -0.097 | -0.054 |
| % Growth | 83.7% | -2.7% | -80.4% | – |
| EPS Diluted | -0.016 | -0.1 | -0.097 | -0.054 |
| Weighted Avg Shares Out | 212 | 121 | 82 | 82 |
| Weighted Avg Shares Out Dil | 212 | 121 | 82 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $3 | $3 | $0 |
| Depreciation & Amortization | $2 | $6 | $2 | $1 |
| EBITDA | $2 | -$2 | -$3 | -$2 |
| % Margin | 1.4% | -2.5% | -3.7% | -2.7% |